Search

Displaying results 1761 - 1770 of 7673 in total
  1. Drug

    Pepsin

    go.drugbank.com/drugs/DB13198
    ApprovedWithdrawn

    Pepsin is approved by the FDA and is used in food at levels not to exceed current good manufacturing practice [L2363].

    Mixtures: Glutamic Acid Hydrochloride Nu Life
  2. Drug

    Rabies virus inactivated antigen, A

    go.drugbank.com/drugs/DB10283
    ApprovedInvestigational

    It is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus. … Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection.

    Products: ABHAYRAB 2.5 IU/0.5 ML IM/ID ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, 1 ADET
  3. Drug

    Methotrimeprazine

    go.drugbank.com/drugs/DB01403
    Approved

    A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlo...

    Categories: Dopamine D2 Receptor Antagonists
  4. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

  5. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. … Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19.

  6. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly … It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk

  7. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    [A225751, A225756, A225766, A191829, L27986] Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.[L27986] … However, due to its modified Fc region, margetuximab binds with higher affinity to both CD16A variants and exhibits weaker binding to the inhibitory CD32B Fc receptor, resulting in more efficient antibody-dependent

  8. Drug

    Viper antivenom

    go.drugbank.com/drugs/DB14114
    ApprovedInvestigational

    ANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation

  9. Drug

    Histidine

    go.drugbank.com/drugs/DB00117
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is required for the production of histamine.

    Mixtures: SOLUCION DP-AMINE, TRAVASOL PLUS 15% LIBRE DE BISULFITO
  10. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [L46491] It is an inert, slightly amphiphilic compound. … [A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536]